Orphazyme to Prepare for Filing of Arimoclomol in US for Niemann-Pick Disease Type C (NPC)
Copenhagen, July 21, 2019 – Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announces that it has had a positive meeting with the FDA and remains on track to submit an NDA for arimoclomol for NPC in H1 2020.
Anders Hinsby, Chief Executive Officer of Orphazyme, said: “We are very pleased with the collaborative interactions we have had with the FDA who provided us with thorough guidance on data presentation in the NDA for arimoclomol in the US for NPC. The valuable advice we have received from health authorities in both the US and Europe increases our optimism that we may soon be able to provide an important treatment option for NPC, a severely debilitating and fatal disease that predominantly affects children.”
Following the encouraging regulatory agency feedback, Orphazyme plans to introduce an Early Access Program for NPC in the fall of 2019, to further accelerate access to treatment with arimoclomol for people living with NPC.
As previously disclosed, Orphazyme also intends to file an MAA in Europe in H1 2020.
Source: Orphazyme A/S
Posted: July 2019
Related articles
- Zevra Therapeutics Provides FDA Update On The PDUFA Action Date For Arimoclomol As A Treatment For Niemann-Pick Disease Type C - March 4, 2024
- Zevra Therapeutics Announces Resubmission of Arimoclomol New Drug Application to the U.S. Food and Drug Administration - December 27, 2023
- Orphazyme Provides Update for Planned NDA Resubmission for Arimoclomol for the Treatment of Niemann-Pick Disease Type C in the United States - February 11, 2022
- Orphazyme Provides Regulatory Update from FDA on Arimoclomol for Niemann-Pick Disease Type C - June 18, 2021
- Orphazyme Announces FDA Acceptance and Priority Review of New Drug Application for Arimoclomol for Niemann-Pick Disease Type C - September 16, 2020
- Orphazyme Completes Rolling Submission of New Drug Application To U.S. FDA for Arimoclomol for Niemann-Pick Disease Type C - July 20, 2020
- Orphazyme Initiates Rolling Submission of New Drug Application for Arimoclomol with US FDA in Niemann-Pick Disease Type C - May 29, 2020
Arimoclomol FDA Approval History
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
